BLTE
Belite Bio Inc

248
Mkt Cap
$5.13B
Volume
242,873.00
52W High
$160.55
52W Low
$49.00
PE Ratio
-76.57
BLTE Fundamentals
Price
$157.10
Prev Close
$146.99
Open
$148.25
50D MA
$108.52
Beta
0.51
Avg. Volume
148,801.58
EPS (Annual)
-$1.18
P/B
18.71
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Belite Bio (NASDAQ:BLTE) Stock Price Down 5.9% - Should You Sell?
Belite Bio (NASDAQ:BLTE) Stock Price Down 5.9% - Time to Sell...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Belite Bio (NASDAQ:BLTE) Sees Strong Trading Volume - Should You Buy?
Belite Bio (NASDAQ:BLTE) Sees Strong Trading Volume - Still a Buy...
MarketBeat·6d ago
News Placeholder
Belite Bio (NASDAQ:BLTE) Rating Increased to Outperform at Mizuho
Mizuho upgraded Belite Bio from a "neutral" rating to an "outperform" rating and increased their target price for the company from $105.00 to $194.00 in a research note on Tuesday...
MarketBeat·7d ago
News Placeholder
FY2025 EPS Estimates for Belite Bio Lowered by HC Wainwright
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Free Report) - Equities researchers at HC Wainwright reduced their FY2025 earnings estimates for shares of Belite Bio in a research note issued on...
MarketBeat·7d ago
News Placeholder
Belite Bio (NASDAQ:BLTE) Reaches New 52-Week High - What's Next?
Belite Bio (NASDAQ:BLTE) Hits New 1-Year High - Time to Buy...
MarketBeat·9d ago
News Placeholder
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of "Hold" by Brokerages
Shares of Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) have been given an average rating of "Hold" by the six ratings firms that are covering the stock, MarketBeat Ratings reports...
MarketBeat·9d ago
News Placeholder
Belite Bio Scores First Successful Phase 3 Trial For Rare Vision-Loss Disease
Belite Bio's Tinlarebant cut lesion growth in a pivotal Stargardt Phase 3 trial, showing strong efficacy and a consistent safety profile.read more...
Benzinga·10d ago
News Placeholder
Belite Bio (NASDAQ:BLTE) Hits New 12-Month High - Still a Buy?
Belite Bio (NASDAQ:BLTE) Hits New 12-Month High - Should You Buy...
MarketBeat·15d ago
News Placeholder
Belite Bio (NASDAQ:BLTE) Shares Up 13.1% - Here's Why
Belite Bio (NASDAQ:BLTE) Shares Up 13.1% - Time to Buy...
MarketBeat·16d ago
News Placeholder
Belite Bio (NASDAQ:BLTE) Sees Strong Trading Volume - What's Next?
Belite Bio (NASDAQ:BLTE) Sees Strong Trading Volume - Time to Buy...
MarketBeat·19d ago

Latest BLTE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.